WE ARE ENDECE
ENDECE, LLC is a privately held biopharmaceutical company at the forefront of new drug discovery and development. Our library of proprietary compounds, invented and owned by ENDECE, was designed to stop disease by up-regulating specific biological pathways to stimulate a biological response for a gain of function. We focus on diseases whose treatment options are limited or non-existent and whose causes may not be well understood including multiple sclerosis (MS) and Alzheimer’s disease.
ENDECE was founded in 2006 and is headquartered in Mequon, Wisconsin.
ENDECE will attend the 35th annual J.P. Morgan Healthcare Conference from January 9-12, 2017 in San Francisco, California. During the meeting, ENDECE will present an update on the clinical development of its lead compound, NDC-1308read more
On November 17, 2016, ENDECE was featured in an article by MedPage Today, titled SfN: Estradiol Analog May Lead to New MS Therapy. The article reports on the early data that suggests NDC-1308 may have remyelinating properties.read more